CDKN2A and cancer: In melanoma, overexpression of mutant BRAF promotes excessive proliferation of melanocytes, inducing the expression of P16INK4A, which subsequently inhibits the activity of CDK4 and CDK6, leading to hypophosphorylation of RB, cell cycle arrest, and thus inhibiting cancer development [383].